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Abstract
Sarcoma is a rare neoplasm that may be found in any location in the body’s soft tissues or
bone (NCCN, 2020). As with all cancer, early diagnosis is important. With sarcoma, there is
increased urgency to obtain a proper diagnosis early on because of the common incidence of
metastasis of the primary tumor. The increased rate of metastasis in sarcoma is due to the
favorable spread of cancer cells through the blood and lymphatic system (Pennacchioli et al.,
2012). The treatment protocol after a new diagnosis of sarcoma depends on the type and may
include multi-targeted therapies such as chemotherapy, radiation, and/or surgery (Gebhardt, et
al., 2022).
There exists a lack of access to sarcoma patient education and an increasing population in
the U.S. with decreased health literacy. These factors contribute to a decreased patient
understanding of their diagnosis and are found to decrease survival. Literature review and
analysis of online sarcoma education shows that existing education is written above what the
NIH considers the general U.S. population’s reading level (Patel et. al., 2015). This led to a
partnership between the authors and Rein in Sarcoma (RIS), a non-profit organization based out
of Minnesota. The authors partnered with RIS to enhance remotely accessible and easy to
understand sarcoma education through online videos aimed for newly diagnosed sarcoma
patients and their families. The five video series describes what sarcoma is, treatment options,
experiences from sarcoma survivors, caregiver experience, and education on various topics such
as: advanced directives, hospice, and palliative care. The videos were professionally edited and
distributed by RIS online to increase accessibility of sarcoma education.
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Chapter 1: Introduction
Introduction
Sarcoma is a connective tissue cancer that originates from bone, fat, cartilage, and muscle
tissue (Rein in Sarcoma [RIS], 2020). Sarcoma can be found anywhere in the body and is
considered a rare cancer (NCCN, 2020). Sarcoma is divided into two main types: soft tissue and
bone (NCCN, 2020). However, there are many subtypes of sarcoma within each main type.
Generally, both soft tissue and bone sarcoma have rapid rates of lymphatic and hematogenous
metastatic spread (Pennacchioli et al., 2012). Researchers are unsure of the precise etiology of
sarcoma formation and more research is needed in this area (RIS, 2020). Diagnosis and treatment
of sarcoma is determined by tumor location in the body, subsequent removal of tissue through
core needle biopsy, and analyzing cellular anatomy when closely viewed under a microscope
(NCCN, 2020). Core needle biopsy is the preferred method for obtaining tissue samples. If an
incisional biopsy is used, it should be planned and performed by the surgeon who will be
performing the final resection. A poorly placed biopsy may promote metastasis, require
subsequent surgical repair, or more extensive surgery at the time of resection (Ryan & Meyer,
2022). Healthcare providers require adequate education to appropriately recognize, diagnose, and
treat sarcoma (American Cancer Society, 2018d). Due to the rarity of sarcoma, many providers
are not experts in diagnosing or treating these tumors. In fact some subtypes of sarcoma are so
rare that there are no specific treatment recommendations (NCCN, 2020). It is important after a
diagnosis of sarcoma to locate an expert with knowledge and experience in that specific
diagnosed subtype of sarcoma (NCCN, 2020).
Rein in Sarcoma (RIS) is an organization based out of Fridley, MN. The organization’s
mission statement is as follows: “Rein in Sarcoma is dedicated to educating the public and
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medical community about sarcomas, supporting sarcoma patients and their loved ones, and
funding research directed toward developing new treatments and finding a cure for sarcoma
cancers'' (RIS, 2020, Our Mission section). Rein in Sarcoma identified a need to expand sarcoma
patient education materials aimed toward the newly diagnosed at an appropriate health literacy
level. Rein in Sarcoma and the authors determined the best approach during COVID to expand
and enhance sarcoma patient education was to create online videos aimed toward newly
diagnosed sarcoma patients that would be published through the RIS YouTube and the
organizations webpage.
Chapter one begins with a background to the problem, the needs assessment that inspired
this community service project, the problem statement, the purpose, significance of this project,
limitations encountered, and concludes with definitions of common terminology used throughout
this paper.
Background to the Problem
Sarcoma is a rare connective tissue cancer that arises from mesenchymal cells and
accounts for less than 1% of adult cancers and 12% of pediatric cancers (Ryan & Meyer, 2022).
Sarcoma is divided into two main types: soft tissue sarcoma (STS) or bone sarcoma. Soft tissue
sarcoma is a broad category that contains over 100 different histological subtypes (Schöffski et
al., 2014). Bone sarcomas are less common than STS and do not have as many subtypes (Fossum
et al., 2020). Osteosarcoma is the largest subtype of bone sarcoma and accounts for half of all
diagnoses of bone cancers (Hornicek & Agaram, 2020).
Soft tissue sarcoma typically presents as a gradually enlarging painless mass (Ryan &
Meyer, 2022). Some patients will experience pain and paresthesias due to compression of the
surrounding structures by the tumor, edema of the affected area, and rarely, systemic symptoms
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like fever and weight loss (Ryan & Meyer, 2022). The exact etiology of sarcoma is unclear, but
literature supports that there are specific genetic contributions. Increased incidence of sarcoma is
seen in those with the genetic syndrome Li-Fraumeni, neuroblastoma type I, retinoblastoma,
previous radiation exposure, exposure to chemical carcinogens, and lymphedema (Ryan &
Meyer, 2022).
The primary tumor sites of osteosarcoma differ depending on the age of the patient. In
children, the metaphysis of the long bones is the most common; however, the axial skeleton and
craniofacial bones are commonly affected in adults (Wang et al., 2022). Symptoms of
osteosarcoma is a localized bone pain at the primary tumor site that may wax and wane, a
palpable mass, or a pathological fracture that can decrease ability to move the limb or cause a
limp when walking. Systemic symptoms are typically absent (Wang et al., 2022). Predisposing
factors for osteosarcoma include previous chemotherapy and radiation exposure, Paget disease,
and the same genetic conditions seen with soft tissue sarcomas (Wang et al., 2022).
A favorable prognosis of sarcoma is dependent on early recognition and diagnosis as well
as prompt treatment due to the aggressive and metastatic nature of the cancer that often involves
lymphatic or hematogenous spread throughout the body. Sarcoma is often diagnosed at an
advanced stage due to this lymphatic or hematogenous metastasis, secondary to a delayed
diagnosis or misdiagnosis. When sarcoma metastasis occurs, it is preferentially located in the
lungs, and is associated with increased mortality rates (George & Grimer, 2012). Through proper
education, medical providers may be more readily able to recognize sarcoma, add it to their list
of differentials, diagnose at an earlier stage, and initiate treatment sooner (Fossum et al., 2020).
The differentials list is broad when a provider encounters a mass and may be more likely to
include common and benign conditions. The provider differentials list may exclude rare cancers
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such as sarcoma, as a common approach to diagnosis in medicine is to ‘look for horses not
zebras’. It is imperative that patients are referred to a specialist for an appropriate biopsy and
evaluation of a mass (Fossum et al., 2020).
After an initial diagnosis of sarcoma subtype, careful analysis of the tumor's cells and
genetics occurs which helps guide treatment. All factors are looked at in regards to determining
treatment of the primary tumor including, what subtype of sarcoma it is, where it is located, and
if the tumor is localized or widespread. Treatment of soft tissue sarcoma often includes a
combination of radiation, chemotherapy, and surgical excision in contrast to osteosarcoma
treatment which is resistant to radiation and involves mostly surgical intervention and
chemotherapy (DeLaney et al., 2020; Janeway & Maki, 2020). Research clinical trials are
important in treatment of sarcoma. Patients must meet specific eligibility criteria to participate in
a clinical trial and must be provided an opportunity for shared decision making with their
provider.
After a sarcoma diagnosis, a patient may choose to obtain a second opinion to confirm
the diagnosis or explore available academic clinical trials for treatment, however, this is not
mandatory and is a patient’s personal preference (Peier-Ruser & von Greyerz, 2018). Patient’s
and their families may see getting a second opinion as valuable in providing reassurance and
building confidence in an existing diagnosis thus enhancing the trusting relationship with the
provider. When discussing and deciding on treatment options with their provider, patients must
have a good understanding of who makes up their sarcoma care team, the treatment benefits and
risks, and the timeline of treatment course.
Following a sarcoma diagnosis patients experience grief. It is commonly accepted that
there are five stages of grief according to Kübler-Ross’ On Death and Dying. However, patients
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may not encounter all of the five stages: denial, anger, bargaining, depression, and acceptance;
and there is no set order (Singer, 2018). Every patient’s experience with grief looks different and
the length of time spent in each stage may vary (Singer, 2018). Patient support after a new cancer
diagnosis is essential and may include resources like cancer support groups, individual or group
therapy, or patient advocacy through cancer organizations (Taylor et al., 1986). Patients may find
support groups through online resources, medical provider recommendations, or patient
advocacy groups. These support services offer a safe space outside of the medical setting to share
personal experiences and both receive and provide encouragement to others.
According to Giuliani et al. (2020), patient education is “a critical aspect of quality
cancer care”. It better equips patients after a new diagnosis to understand and manage their
medical care. Effective oncological patient education involves one-on-one teaching from the
provider alongside supplemental educational materials. Patients often report they did not initially
have a good understanding of their diagnosis, which may be attributed to low health literacy, the
quality and quantity of patient education delivered, the patient’s comprehension, health, and
emotional state during cancer diagnosis (Giuliani et al., 2020). One-on-one delivery of education
poses challenges to the unwell patient as they are required to attend additional appointments.
This raises concerns of inequity when it comes to patient education at time of diagnosis. Patel et
al. (2015) presents that the general population in the United States has an overall low health
literacy. Health literacy is a patient's ability to access, gather, understand health information and
services while applying this information to make appropriate health decisions. When patients
receive educational materials at their respective health literacy level this leads to a greater
understanding of their cancer diagnosis and the treatment course (Giuliani et al., 2020).
Receiving appropriate educational materials has been shown to reduce anxiety, increase patient
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satisfaction with care, and improve self-care (Patel et al., 2015). In contrast, patients report
distress, misunderstanding, and treatment non-compliance when they are unable to access
information at an appropriate level of health literacy. While evaluating patient understanding of
educational resources, Patel et al. (2015) presented data showing across 72 websites and 774
articles that online sarcoma resources are written above an eleventh-grade reading level, which is
incompatible with the average reading level of Americans. The National Institute of Health
(NIH) recommends that medical education materials be written at a seventh-grade level or below
to more closely match the reading level of the general American population. This current
disparity reveals a need for improvement of and increased access to online sarcoma patient
education material written at an appropriate reading level (Patel et al., 2015).
Needs Assessment
Karen Wycoff founded Rein in Sarcoma (RIS) in 2001 to “raise awareness and fund cures
for sarcoma patients” (RIS, 2020, Karen’s Story section). Wycoff was a Minnesota native and
while attending college at Willamette University in Oregon in 1997, she found a growth in her
axilla during a self-exam. She underwent a biopsy of the mass, which was assumed to be benign;
however, pathology confirmed her diagnosis was sarcoma. In 2001, Wycoff hosted the first
annual RIS fundraising event. Two months later, two weeks before her 26th birthday, she passed
away, but her foundation still remains active today (RIS, 2020). Rein in Sarcoma currently has
close relationships with various organizations including local medical programs at the University
of Minnesota, the Mayo Clinic, and Children’s Minnesota, which collaborate on advancing
sarcoma research. Rein in Sarcoma is one of the largest sarcoma foundations in the Midwest and
primarily serves patients in Minnesota, Iowa, North and South Dakota, and Wisconsin, but is
known nationally and globally and continues to build new partnerships (RIS, 2020).
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Rein in Sarcoma provides a free patient guidebook to people who have been diagnosed
with sarcoma. The purpose of the patient guidebook is to extend support and provide sarcoma
education to patients and their families (RIS, 2020). The patient guidebook covers the following
topics: an overview of bone and soft tissue sarcomas, sarcoma subtypes, treatment options,
navigating medical appointments, resources for patients and their caregivers who are undergoing
treatment, resources for finding support, and organizational tools that can be utilized during
treatment (RIS, 2020). Rein in Sarcoma identified a need to add accessible online sarcoma
patient education material. The authors collaborated with RIS to create videos to supplement
their current educational materials, in hopes of enhancing access to and improving understanding
in newly diagnosed patients (see Appendix A).
Problem Statement
Rein in Sarcoma was looking to expand educational and supplemental videos for newly
diagnosed sarcoma patients and family members. When patients receive a new cancer diagnosis,
the information presented by the medical professional one-on-one may be misunderstood or
overwhelming. The information may be subject to distortment because of the acute trauma of a
cancer diagnosis. Patients will often “find that [they] can only take in small amounts of
information [and] need to have the same information repeated to [them]” (Cancer Research UK,
2017, Shock and Denial section). There was a need for improved and accessible sarcoma
education created at a health literacy level that is easily understood by sarcoma patients,
especially during the time of a new diagnosis. The videos are available on the RIS website and
their YouTube channel, which allows patients and their families the ability to watch remotely.
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Purpose
The purpose of this project was to create educational videos that newly diagnosed
sarcoma patients and their families can watch remotely in hopes of addressing initial questions
they may have following a diagnosis. The intention was to reinforce medical information that is
presented by the provider one-on-one in an accessible format that improves patient
understanding of sarcoma. The videos featured sarcoma survivors, caregivers, a discussion of
advance care planning, an overview of sarcoma, and standard sarcoma treatment options. This
project was given to RIS to be used as a supplemental patient resource that the organization can
provide to newly diagnosed sarcoma patients.
Significance of the Project
With the guidance and support of RIS, this project allows newly diagnosed sarcoma
patients the opportunity to learn more about sarcoma remotely. The goal was to support patients
during a new diagnosis through the experiences of the various video participants who shared
their stories while instilling hope. The aim for this project was to enhance education and address
patients most commonly asked questions. In addition, this project impacts physicians, physician
assistants, nurse practitioners, nurses, and all other healthcare team members by providing more
education and stressing the importance of early diagnosis of sarcoma. During time of diagnosis,
providers have the opportunity to enhance patient education by providing the RIS guidebook,
and this project allows for the opportunity to refer patients to the videos online or through a QR
code that will direct patients to the videos.
Limitations of the Project
In acknowledging existing limitations to this project, the first identified limitation to
achieving project goals would be viewers with limited resources lacking access to computers or
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the internet. In addition, the organization of the videos and how the videos are displayed on the
RIS YouTube channel determines if patients will find them accessible. Lastly, if patients or
healthcare team members are unaware that the videos exist, they would not benefit from the
videos intended purpose.
Definition of Terms
The following definitions are used commonly throughout this paper:
Acceptance: The final stage of grief. The “quality of being able to recognize [something] as true”
(Merriam-Webster, n.d., Definition 1.a.).
Anger: A stage of grief. A “strong feeling of displeasure or rage” (Merriam-Webster, n.d.,
Definition 1.b.).
Advanced care directive (advance directive or AD): “Documents a person completes while still
in possession of decisional capacity about how treatment decisions should be made on their
behalf in the event they lose the capacity to make such decisions” (Silveira, 2020, Advance
Directive section).
Bargaining: A stage of grief in which one “negotiates over terms” (Merriam-Webster, n.d.,
Definition 1.c.) or makes a promise for an exchange of wellness.
Chemotherapy (chemo): Medicine or drugs that are used to treat cancer that are cytotoxic or have
the ability to kill tumor cells (American Cancer Society, 2020b).
Denial: A stage of grief. A “refusal to admit the truth or reality of something (such as a statement
or charge)” (Merriam-Webster, n.d., Definition 1.d.).
Depression: A stage of grief “marked by sadness, inactivity, difficulty in thinking and
concentration, a significant increase or decrease in appetite, time spent sleeping, feelings of
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dejection and helplessness, and sometimes [having] suicidal tendencies” (Merriam-Webster, n.d.,
Definition 1.e.).
Do not hospitalize (DNH): An “order which [is] created in effort to reduce hospitalizations
unlikely to improve patient survival or quality of life” (Conner & Weis, 2020, Definitions
section).
Do not intubate (DNI): An “order which seeks to prevent unwanted mechanical ventilation”
(Connor & Weis, 2020, Definitions section).
Do not resuscitate (DNR): A prevention of undesired cardiopulmonary resuscitation, including
rescue breathing and/or chest compressions, defibrillation, and any type of advanced
cardiovascular life support (Connor & Weis, 2020, Definitions section).
Genome: “The genetic material of an organism” (Merriam-Webster, n.d., Definition 1.f.).
Grief: A “strong, sometimes overwhelming emotion for people, regardless of whether their
sadness tems from the loss of a loved one or from a terminal diagnosis they or someone they love
have received” (Mayo Clinic, 2016, para. 1). Grief can be both “a universal and a personal
experience” (Mayo Clinic, 2016, para. 3) and can last anywhere from a few days to months to
years. “Pain is tempered as time passes and as the bereaved adapts to the news of a terminal
diagnosis” (Mayo Clinic, 2016, para. 5).
Healthcare power of attorney (HCPOA): A person or persons that a patient designates to “make
medical decisions on their behalf in [the] event of [their] lost decision-making capacity” (Connor
& Weis, 2020, Definitions section).
Malignant: “Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other
parts of the body” (National Cancer Institute, n.d., Definition 1.a.).
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Margin: “The margin is described as negative or clean when the pathologist finds no cancer cells
at the edge of the tissue, suggesting that all of the cancer has been removed” (National Cancer
Institute, n.d., Definition 1.b.).
Metastasis: “The spread of a disease-producing agency (such as cancer cells) from the initial or
primary site of disease to another part of the body” (Merriam-Webster, n.d., Definition 1.h.).
Neoplasm: “An abnormal new growth of tissue that grows by cellular proliferation more rapidly
than normal” (Dictionary.com, 2020, Definition 1).
Osteosarcoma: “A sarcoma derived from bone or containing bone tissue” (Merriam-Webster,
n.d., Definition 1.i.).
QR Code: “Short for quick response code, it is a type of barcode that contains a matrix of dots. It
can be scanned using a QR scanner or a smartphone with built-in camera. Once scanned,
software on the device converts the dots within the code into numbers or a string of characters.
For example, scanning a QR code with your phone might open a URL in your phone’s web
browser” (TechTerms.com, 2022, paragraph 1).
Radiation therapy: A type of cancer treatment that “uses high-energy particles or saves, such as
x-rays, gamma rays, electron beams, or protons, to destroy or damage cancer cells” (American
Cancer Society, 2019c, “What is radiation therapy?” section) and is often “used alone or with
other treatments, such as surgery, chemotherapy, hormones, or targeted therapy” (American
Cancer Society, 2019c, Radiation Therapy Section).
Resection: “Surgical removal of part of an organ or structure” (Merriam-Webster, n.d., Definition
1.j.).
Sarcoma: “A malignant tumor arising in tissue (such as connective tissue, bone, cartilage, or
striated muscle) of mesodermal origin” (Merriam-Webster, n.d., Definition 1.k.).
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Soft tissue sarcoma: “A rare type of cancer that begins in the tissues that connect, support, and
surround other body structures. This includes muscle, fat, blood vessels, nerves, tendons, and the
lining of your joints” (Mayo Clinic, 2018, para. 1).
Surveillance: “In medicine, closely watching a patient’s condition but not treating it unless there
are changes in test results. Surveillance is also used to find early signs that a disease has come
back. It may be used for a person who has an increased risk of a disease, such as cancer. During
surveillance, certain exams and tests are done on a regular schedule” (National Cancer Institute,
n.d., Definition 1.c.).
TNM Staging: The “most often used by doctors to stage cancer. It is maintained by AJCC
(American Joint Committee on Cancer) and UICC (Union for International Cancer Control). In
this system, the letters T, N, and M describe a different area of cancer growth.” T= tumor size,
N=node status, and M= presence of distant metastasis (National Comprehensive Cancer
Network, n.d.,TNM staging system section).
Tumor suppressor gene p53: “A tumor suppressor gene, i.e., its activity stops the formation of
tumors. If a person inherits only one functional copy of the p53 gene from their parents, they are
predisposed to cancer and usually develop several independent tumors in a variety of tissues in
early adulthood” (National Center for Biotechnology Information (US), 1998, para. 1).
Conclusion
Receiving a new cancer diagnosis is overwhelming, and patients often enter an emotional
state of shock after hearing the word ‘cancer’ (Cancer Research UK, 2017). Patients can miss
essential information or the opportunity to ask questions at the time of diagnosis due to the
unexpected and life-changing news. The objective of this community service project was to
collaborate with RIS to create educational videos for newly diagnosed sarcoma patients and their
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families with the intention to provide support through supplemental sarcoma educational
materials, in addition to the RIS guidebook and one-on-one provider education. Chapter two
provides a review of both foundational sarcoma literature and up-to-date research. It provides a
detailed overview of soft tissue and bone sarcoma, common treatments, important topics of
consideration after a new cancer diagnosis, and support information for family members and
caregivers.
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Chapter 2: Literature Review
Introduction
Sarcomas are a rare and diverse group of malignant neoplasms that arise from connective
tissue. Specifically, sarcoma arises from mesenchymal cells that differentiate into a specific type
of connective tissue. These connective tissues are found in all areas of the body and include the
framework of support tissues that surround all organs, muscle, blood vessels, make up adipose,
and bone (Zahm & Fraumeni, 1997). The majority of diagnosed sarcoma cases arise from soft
connective tissues and make up roughly 80%, while the other 20% of new cases originate from
bone (Ryan & Meyer, 2022). The ability of medical providers to recognize and include sarcoma
as a differential diagnosis when a patient initially presents is vital to early diagnosis and is very
important due to the highly metastatic nature of sarcoma (Ryan & Meyer, 2022). If sarcoma is
suspected, a skillful biopsy containing a cellular sample must be done which is subsequently
used to identify the specific subtype of sarcoma and genetic tumor markers. All of this
information serves to provide accurate diagnosis, complete staging, and direct course of
treatment aimed toward the specific genetics of the developing sarcoma (Skubitz & D’Adamo,
2007).
This literature review includes a general overview of the main categories sarcoma is
classified into: soft tissue sarcoma (STS) and bone sarcoma. For this review the authors included
foundational sarcoma literature as well as included current literature to provide a broad view into
the subject. Next, the literature review includes the current standard in treatment of sarcoma, as
well as the importance of proper patient education and support after a new sarcoma diagnosis.
Also discussed are important and commonly encountered topics such as the stages of grief,
support and patient advocacy, and advanced care planning.
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Soft Tissue Sarcoma Formation
The environment of an organism has a large impact on small specialized structures inside
the body called cells. Natural cellular protective mechanisms exist inside the cell’s nucleus,
which are advantageous to preserve the normal structure of the cell’s genetic material, thereby
maintaining cellular integrity, which encourages survival and inheritance of traits (Laurini et al.,
2020). These protective mechanisms include the cell’s direct ability within the nucleus to repair
its DNA through complex chemical structural changes (Laurini et al., 2020). When genetic
mutations occur and cannot be repaired by these protective intra-nucleus repair mechanisms, the
genetic makeup of the cell becomes permanently damaged and can lead to genetic changes of
subsequent cell lineages via mutations. The mutations may act on specific gene segments of the
DNA inside the nucleus or may rearrange the chromosomes, which causes permanent genomic
instability of the cell. The overall impact is modification and initiation of abnormal cell cycles,
which contribute to cancer formation (Laurini et al., 2020). There is not a clear etiology why
sarcomas form but they are thought to arise spontaneously after new mutations occur (Ryan &
Meyer, 2022). Past and present research supports a specific genetic germline mutation of the
tumor suppressor gene, TP53, that may play a central role in the development of a high
proportion of various cancers (Zahm & Fraumeni, 1997). Mutation of the TP53 gene is the most
frequently detected molecular alteration in STS (Pollock et al., 1998). Cells in the primary tumor
with the TP53 gene point mutation expand and become the dominating cellular metastatic
component (Pollock et al., 1998). This mutation can be linked to poor prognosis in STS patients
as some studies have frequently found this gene point mutation in metastatic STS. As a result of
metastasis, these neoplasms are diagnosed as high-grade sarcomas and correspond with a poor
prognosis (Pollock et al., 1998).
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Soft Tissue Sarcoma Overview
Soft tissue sarcomas are relatively rare but account for 80% of new sarcoma cases per
year (Ryan & Meyer, 2022). There are approximately 11,000 cases per year in the United States;
this may be a conservative estimate as these cancers can often go misdiagnosed (Nystrom et al.,
2013). Soft tissue sarcomas are characteristically diverse cancers, as they arise from embryonic
mesenchymal cells, which differentiate into different types of connective tissue throughout the
body (Ryan & Meyer, 2022). A recent estimate is that there are over 100 different histological
subtypes of malignant STS (Schöffski et al., 2014). According to Dr. Charles Forscher,
co-medical director of the sarcoma program at Cedars-Sinai Medical Center, the most common
subtypes of STS are angiosarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans,
epithelioid sarcoma, malignant peripheral nerve sheath tumors, myxofibrosarcoma,
rhabdomyosarcoma, solitary fibrous tumor, synovial sarcoma, and undifferentiated pleomorphic
sarcoma (Forscher, 2020). Although soft tissue sarcoma is rare overall, many researchers believe
that the incidence is underestimated (Zahm & Fraumeni, 1997). This underestimation may be
attributed to the misdiagnosis of STS as cancer of a particular organ instead of the connective
tissues around it (Zahm & Fraumeni, 1997). It remains difficult to determine the frequency of
STS due to their rarity and the number of cases that remain undiagnosed, or get misdiagnosed
(Forscher, 2020).
Soft tissue sarcoma can affect males and females of all age groups, although the largest
population affected is adults 45-90 years of age (Schöffski et al., 2014). Risk factors for STS are
family history, genetic mutations, and prior radiation exposure (Ryan & Meyer, 2022). Radiation
increases the risk for secondary STS, as evidenced in patients who have received radiation
treatment for breast and other cancers (Meyer et al., 2009).
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Soft tissue sarcoma can develop anywhere in the body, with the arms and legs being the
most common location (Ryan & Meyer, 2022). Other common locations and the percentage of
occurrence are: thigh/buttocks/groin (46%), torso (18%), retroperitoneum (13%), and head/neck
(9%) (Ryan & Meyer, 2022). Soft tissue sarcomas typically present as a slow-growing painless
mass. These tumors can eventually become large enough to cause pain and compression
symptoms such as paresthesias, or cause edema when located in an extremity (Ryan & Meyer,
2022). Less commonly, STS patients present with fever, weight loss, or regional lymph node
involvement (Ryan & Meyer, 2022).
Often there is a delay in a STS diagnosis, which may be attributed to the relatively small
number of cases seen and a suspicion that the growth is benign or does not require an extensive
workup (Ryan & Meyer, 2022). A soft tissue mass is 100 times more likely to be benign than
malignant. Due to this fact, roughly 10% of sarcoma patients have detectable metastases at the
time of diagnosis (Fossum et al., 2020; Pennacchioli et al., 2012). The United Kingdom
Department of Health has created criteria for soft tissue masses that may help medical providers
determine if a patient needs an urgent referral to an oncologist for appropriate biopsy and
initiation of treatment. This criteria includes a soft tissue mass greater than 5 cm (golf ball size or
larger), a lump that is painful or has increased in size, any lump deep to the muscle fascia, and
any recurrence of a lump after excision (Ryan & Meyer, 2022). There are proper biopsy
techniques utilized when making a STS diagnosis and care should be given, even if sarcoma is
unsuspected at the time of diagnosis (Ryan & Meyer, 2022). After biopsy and diagnosis, experts
recommend that all newly diagnosed STS patients have a chest computed tomography (CT) to
evaluate for the possibility of lung metastasis (Ryan & Meyer, 2022). The prognosis of STS
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greatly depends on the size of the mass, evidence of metastasis, and the histological subtype of
the STS.
Genetics of Osteosarcoma Formation
It is challenging to diagnose and treat osteosarcoma due to its rarity (Franceschini et al.,
2019). As seen in STS, the exact pathogenesis is not well established, but for osteosarcoma, it is
believed to be a sporadic occurrence including both genetic and environmental factors (Gorlick,
2019). The cells from which osteosarcoma originates are mesenchymal cells that differentiate
into osteoblasts (Gorlick, 2019). Osteoblasts are cells within bone that are responsible for new
bone formation. Changes in specific genes within these cells contribute to the development of
osteosarcoma (Gorlick, 2019).
There have been recent molecular breakthroughs in determining how bone tumors
generally arise. Bone tumors are divided into neoplasms that have either a simple or complex
karyotype (Franceschini et al., 2019). Osteosarcoma has a complex karyotype that shows
multiple genetic abnormalities (Franceschini et al., 2019). The genetic abnormalities include an
irregular increase in copies of a gene segment, deletions of a gene segment, and random
translocations. All of these genetic mutations affect the genes involved in maintaining the
genomic stability of the osteoblast (Franceschini et al., 2019). There are hidden driver genes or
mutant forms of genes that encourage cancer growth, which lead to further genomic instability
(Franceschini et al., 2019). Chromothripsis, a mutational process in which chromosomes are
‘shattered’ into thousands of segments that are irregularly put back together, is another factor that
contributes to the genomic instability of osteosarcoma formation (Franceschini et al., 2019).
Chromothripsis is a mechanism observed in only 3% of other cancers, but is found in over 30%
of osteosarcoma cases (Franceschini et al., 2019).
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The most commonly altered genes observed in osteosarcoma are genes TP53 and RB1,
which ordinarily function to regulate and maintain genome stability (Franceschini et al., 2019).
These genetic variations occur more frequently in association with osteosarcoma than in other
types of cancer (Gorlick, 2019). Certain germlines are predisposed to develop osteosarcoma and
are commonly found in hereditary syndromes such as Li-Fraumeni, retinoblastoma, and
Rothmund-Thomson (Franceschini et al., 2019). The gene RB1 is the retinoblastoma gene that is
associated with a rare childhood cancer that forms in the eye.
Bone Sarcoma Overview
Bone sarcoma is the second largest sarcoma group and includes osteosarcoma, Ewing’s
sarcoma, and chondrosarcoma (Casali et al., 2018). Mavrogenis and Ruggieri (2015) point out in
the article “Therapeutic Approaches for Bone Sarcomas” that bone sarcomas can be osteolytic,
produce calcified matrixes (osteosarcomas), form from a cartilaginous matrix
(chondrosarcomas), or may include both an osteolytic and osteoblastic mechanism. This review
will specify when referring to a specific subtype of bone sarcoma or population affected.
When considering all bone forming tumors of the skeleton, osteosarcoma is the most
common malignant neoplasm that forms in bone (Franceschini et al., 2019). These tumors are
non-epithelial malignant neoplasms that originate from either the precursors of bone cells or
from the bone cells themselves (Mavrogenis & Ruggieri, 2015). This review will focus on
osteosarcoma as it is the most common primary malignant tumor of bone sarcomas (Franceschini
et al., 2019). The five-year survival rate for osteosarcoma patients has maintained a steady 71%
(Franceschini et al., 2019).
The affected population of osteosarcoma is bimodal, occurring in both children and adults
(Mavrogenis & Ruggieri, 2015). Primary high-grade osteosarcomas have a pattern that occurs in
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adolescents aged 10-19 years, with a second peak in adulthood, usually over the age of 60, and
sometimes form secondarily to radiation (Franceschini et al., 2019; Gorlick, 2019).
Osteosarcoma affects both males and females, with a slightly higher occurrence in males
(Franceschini et al., 2019). Osteosarcoma also has a higher prevalence in African American and
Latino populations (Gorlick, 2019). In adults, the osteosarcoma neoplasm, also known as an
osteoid, is most commonly seen in the femur, tibia, pelvis, upper long bones of the humerus,
radius, ulna, facial bones, and the skull (DynaMed, 2018a). In children, the most affected bones
are the pelvic bones and upper and lower long bones (humerus, distal femur, and proximal tibia)
(DynaMed, 2018b). The formation of osteosarcoma commonly occurs at the metaphysis, or
growth plate, of the long bones in children (DynaMed, 2018a). Osteosarcoma can also invade the
medulla of long bones or may form near the bone surface (Franceschini et al., 2019).
The common presentation of osteosarcoma is a swelling and enlarging mass that is
described as a dull, aching, and persistent localized pain (Mavrogenis & Ruggieri, 2015).
Patients report a feeling of ‘deep pain’ that is more noticeable with rest at night and gradually
develops over weeks to months (Franceschini et al., 2019). Patients may present with decreased
or limited mobility and localized palpable heat (Franceschini et al., 2019). The enlarging growth
may feel tender upon palpation during physical exam (Franceschini et al., 2019). If the
osteosarcoma has progressed to a later stage and the provider is seeing the patient for the first
time it may present as a pathologic fracture (DynaMed, 2018a).
Osteosarcomas are classified as high-grade, intermediate-grade, or low-grade cancers
(Gorlick, 2019). The grade classification is determined by looking at the cancer cells
microscopically and deciphering the extent of cell growth and metastasis (Gorlick, 2019).
High-grade osteosarcomas are the most common type in children and are the fastest-growing
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metastatic form (Gorlick, 2019). Ten percent of patients who present with high-grade tumors
present with metastatic disease, and 70% of patients with high-grade sarcoma will eventually
develop metastatic disease (Pennacchioli et al., 2012).
Metastatic Component of Sarcoma
Metastasis of all sarcoma subtypes happens when cancer cells spread to secondary
locations via blood vessels or the lymphatic system from where the neoplastic cells first arose in
the body (Pennacchioli et al., 2012). Understanding sarcoma's metastatic potential is extremely
important to help predict outcome and mortality (Pennacchioli et al., 2012). There are multiple
processes involved in metastasis, but initially it involves a molecular change that disrupts the
connection between the primary tumor site and the surrounding cells (Pennacchioli et al., 2012).
The molecular changes that impact the cancer cells may come from cell adhesion molecule
(CAM) signals, or tissue remodeling by proteinases, chemokines, or growth factors
(Pennacchioli et al., 2012). The tissue remodeling molecules ordinarily regulate cellular
processes such as proliferation, apoptosis, migration, and invasion (Pennacchioli et al., 2012).
The metastatic sarcoma cascade is still a largely unknown mechanism. After cellular disruption,
the tumor cells can metastasize via lymphatic drainage from the primary site to the lymph nodes,
or spread through the vasculature into distant organs (Pennacchioli et al., 2012). In sarcoma, the
main metastasis sites are the lungs and bone, which predominantly spreads hematogenously
through the blood vasculature (Pennacchioli et al., 2012).
Specific types of sarcoma spread differently, either lymphatically or hematogenously as
previously stated. For example, epithelioid sarcoma, clear cell sarcoma, angiosarcoma, and
rhabdomyosarcoma metastasize in the body via the lymphatic system, specifically into
neighboring lymph nodes, but most other sarcoma types spread through the vascular system
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(Pennacchioli et al., 2012). The cancer cells get into the bloodstream where they can become
lodged in the capillaries because of their small size or they may adhere to the endothelial lining
in the capillary lumen (Pennacchioli et al., 2012). The preference for vascular spread by sarcoma
can be catastrophic because of its potential to cause metastatic foci in the lungs (Pennacchioli et
al., 2012). Lung metastasis is known to worsen the prognosis and is an indication of widespread
cancer within the body. In this instance, a patient’s outcome is usually limited to no more than
five years (UCLA Health, n.d.).
Common Types of Treatment for Sarcoma
Surgery
Surgery is a common component in sarcoma treatment plans unless the sarcoma has
metastasized extensively or is in a region in which wide excision of the tumor would be difficult
to obtain clear margins (American Cancer Society, 2018c). Areas of the body that are
challenging for surgical removal include the spine, pelvis, skull base, jaw, and STS in the
thoracic or abdominal cavity (American Cancer Society, 2020d). These areas are complex
because removing sarcoma requires a wide excision to remove the tumor entirely, along with one
or more centimeters of healthy tissue margins around the tumor (DeLaney et al., 2020). After the
tumor removal, the pathologist inspects the tissue margin under a microscope looking for cancer
cells. If cancer cells are present in the resected tissue margin, it is labeled as having positive
margins which suggests that there may still be cancer cells left behind at the resection site
(American Cancer Society, 2018c). When this occurs, there is an increased risk for cancer
regrowth and metastasis. When no cancer cells are present microscopically from the resection,
the tumor is labeled as having negative margins and the chance of sarcoma regrowth is
diminished (American Cancer Society, 2018c).
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A surgical resection of osteosarcoma can pose a difficult challenge due to the need of a
wide excision to remove the tumor and its surrounding tissue, which can result in limb
amputation. Limb salvaging procedures are becoming more popular, but there is no clear data
exhibiting a survival rate difference between an amputation and a limb salvaging procedure
(Hornicek & Agaram, 2020). The surgeon may use several different techniques to remove the
tumor, which is dependent on the size, location, and whether the surgeon feels an amputation or
limb salvaging procedure would be the best option. If the surgeon is going to attempt a limb
salvaging approach, the patient may receive bone grafts or an internal prosthesis to replace the
removed bone (American Cancer Society, 2020d). Limb salvaging procedures often require
additional follow-up surgeries later to replace the prosthesis, especially when placed in children
that are still growing (American Cancer Society, 2020d). Rehabilitation after limb amputation or
limb salvage procedure is often difficult and may take months to fully recover (American Cancer
Society, 2020d).
Chemotherapy
Chemotherapy is a combination of medications given in cycles through intravenous
administration that help kill cancer cells throughout the body (American Cancer Society, 2020b).
Chemotherapy not only targets cancer cells, but also healthy cells. Killing healthy cells causes a
wide range of side effects that are commonly associated with chemotherapy such as nausea,
vomiting, hair loss, fatigue, mouth sores, increased infection risk, loss of appetite, and bruising
(American Cancer Society, 2018a).
Chemotherapy is prescribed more often in osteosarcoma patients than in STS patients
because of its proven efficacy. Adjuvant chemotherapy in osteosarcoma patients has shown to
significantly increase survival when combined with surgical resection (Janeway & Maki, 2020).
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Research has not shown an optimal chemotherapy regimen for osteosarcoma; however,
three-drug regimens are better than two-drug regimens (Janeway & Maki, 2020). The commonly
used three-drug regimen chemotherapy for osteosarcoma includes methotrexate, doxorubicin,
and cisplatin (Janeway & Maki, 2020). The standard chemotherapy approach for osteosarcoma
has not been agreed upon worldwide and the development of adjuvant chemotherapy has been
largely empiric (Janeway & Maki, 2020). Oncologists usually prescribe chemotherapy
adjuvantly for 29 weeks post surgery, but will also use chemotherapy neoadjuvantly for ten
weeks prior to surgery to shrink the tumor and control metastasis (Janeway & Maki, 2020).
For STS, radiation and surgery are usually the preferred treatment. Chemotherapy is not a
widely accepted treatment standard for STS except for in clinical trials and specific sarcoma
subtypes such as Ewing sarcoma or rhabdomyosarcoma (Gebhardt et al., 2022). There is
currently limited data on the optimal chemotherapy agent and regimen for STS, however
research is being carried out in this area.
Radiation
Radiation uses high-energy particles to target malignant cells at the specific location of
the tumor (Mitin, 2020). Radiation is an outpatient procedure where the patient visits a cancer
treatment center or hospital multiple days a week for several weeks to receive radiation treatment
(American Cancer Society, 2019b). Side effects of radiation are highly dependent on the location
of the tumor. Radiation may cause swelling, erythema, blistering, or skin peeling at the targeted
area (Mitin, 2020). A precise technique is used when delivering radiation to prevent damage to
the surrounding organs. Several radiation techniques are used with sarcoma and include external
beam radiation, brachytherapy, and intraoperative therapy (Mitin, 2020). The most frequently
used type of radiation for sarcoma is external beam radiation (American Cancer Society, 2018b).
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Soft tissue sarcoma patients frequently receive radiation, but radiation is not the primary
treatment option used for osteosarcoma patients. Osteosarcoma is typically resistant to radiation
(Janeway & Maki, 2020). The standard osteosarcoma treatment plan includes using
chemotherapy and surgical excision. Adjuvant radiation in osteosarcoma patients has not proven
to increase survival or prevent secondary tumor recurrence (Janeway & Maki, 2020). In contrast,
radiation is very effective in STS and is the main treatment used in conjunction with surgery.
Radiation and surgical treatment plans for STS in the extremities has reduced the need to
perform limb amputations (DeLaney et al., 2020). There is limited available research on whether
neoadjuvant or adjuvant radiation is more effective in STS (DeLaney et al., 2020).
Clinical Trials
Clinical trials are another option to consider when deciding on a cancer treatment plan. A
cancer clinical trial is real-time research involving volunteer cancer patients, in which the goal is
to discover better cancer detection methods, treatment strategies, and prevention (National
Cancer Institute, 2020). The initiation process of a clinical trial is rigorous and starts years before
it can be offered in the treatment of cancer. Researchers perform experimentation on animals
first, proving safety and efficacy, and must be approved by regulatory bodies before making the
trial widely available to patients (National Cancer Institute, 2020).
There are numerous clinical trials available for both STS and osteosarcoma patients in the
United States. The NIH has a ‘find a study’ search engine that finds clinical trials worldwide
(National Institute of Health, n.d.). At time of this publication, there are currently 614
osteosarcoma and 2,214 STS clinical trials worldwide (National Institute of Health, n.d.). A
patient can also find clinical trials on the National Cancer Institute's website or through many
major cancer centers. An oncologist may recommend a clinical trial to a patient, but due to the
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large number of clinical trials available, oncologists may be unaware of specific details for every
available clinical trial, unless they are personally involved in carrying out the trial. Patients that
are interested in participating in a clinical trial can do their own research online to determine the
eligibility requirements (American Cancer Society, 2020c). If a patient finds a clinical trial they
are interested in and meets the eligibility requirements, they would contact the clinical trial
coordinator and use shared decision making with their oncologist to determine if it is appropriate
for their treatment plan (American Cancer Society, 2020c).
Sarcoma Prognosis/Prognostic Variables
There are three important variables that need to be considered when determining the
prognosis with the primary neoplasm: tumor location, tumor size, and evidence of metastasis
(DynaMed, 2018c). Prognosis will vary depending on the type of sarcoma, the histological
subtype, the resection margins, and tumor characteristics. Poor prognostic factors for sarcoma are
an increased size of the primary tumor, presence of positive margins post-surgery, evidence of
metastasis, a poor response to treatment, and an increased patient age (DynaMed, 2018c). The
five-year survival rate for osteosarcoma patients is 71% and has not seen improvement in the last
decade. This indicates a compelling need for the development of novel therapeutic strategies
(Franceschini et al., 2019).
Stages of Grief After Diagnosis
When a patient initially learns about a new cancer diagnosis, many report entering an
emotional state of shock (Cancer Research, UK, 2017). Some have reported that the moment
they learned about their diagnosis was like a scene from a movie, where time stops around them.
Patients are in disbelief and can feel numb, emotionless, or may need information repeated back
to them (Cancer Research, UK, 2017). Psychology Today defines an emotional or psychological
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shock as “when you experience a surge of strong emotions and a corresponding physical
reaction, in response to a (typically unexpected) stressful event (Boyes, 2018). This reaction to a
new diagnosis can last minutes, hours, or days and can be a way that patient’s temporarily avoid
their new reality. Experts recommend that patients continue with their usual day-to-day activities
during this period (Westburg, 1971). Grief is a natural response to loss, and although a newly
diagnosed patient is not grieving for the loss of life, there are other losses associated with a
cancer diagnosis that bring grief (McKee & Kelley, 2020). Losses a patient may be concerned
about include their physical abilities, cognitive functioning, how they will fit in socially, and new
financial burdens that are associated with a cancer diagnosis. Patients may also experience a loss
of “control”, certainty, hope, and expectations for the future” (McKee & Kelley, 2020, p. 504).
According to McKee and Kelley (2020), grief is unique to each individual and symptoms can
vary from person-to-person.
Elisabeth Kübler-Ross (1969), author of several books on the subject of death and dying,
states there are five stages of grief that patients go through at the end of life, especially if they
have been diagnosed with a terminal illness. These original stages were written about those who
are dying or have a terminal illness, but the five stages of grief are widely accepted today as
applicable to newly diagnosed cancer patients. The five stages of grief include denial, anger,
bargaining, depression, and acceptance. Often patients will experience each of the stages in the
order listed above, but there are no set rules stating that a patient has to complete a specific stage
before moving on to another. Patients have reported that grief is cyclical and each of the
individual stages can be experienced differently from person-to-person (Singer, 2018). The
length of each grief stage is dependent on the patient and their coping abilities (Singer, 2018). At
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one time or another in their cancer journey, patients will typically come to accept the reality of
their diagnosis.
Denial
Denial is a coping mechanism and “adaptive strategy to detect against overwhelming
events and feelings” (Vos & de Haes, 2007, p. 12). Psychoanalyst Anna Freud described denial
as “an unconscious defense against painful and overwhelming aspects of external reality'' (Vos &
de Haes, 2007, p. 12). During a new cancer diagnosis, a patient and their family should be given
the opportunity to ask questions and process this new reality with a medical provider. Patient
denial can act as a barrier to initiating treatment. If a patient feels pressured to start treatment
before coming to terms with their diagnosis this may lead to delayed course of treatment, anger,
and aggravation (Singer, 2018). When addressing the denial a patient may be experiencing,
providers should “strengthen [their] psychosocial resources and avoid denial in one’s own
perspective” (Singer, 2018, p. 2). The provider is recommended to take a neutral stance and
acknowledge the patient’s denial, but not join them with their own denial. Providers should allow
for extra time and support services to ensure a patient has time to ask questions, with the aim of
assisting them in overcoming this stage of grief (Singer, 2018).
Anger
Anger and aggression are innate reactions that many patients experience after a cancer
diagnosis. Patients will often fight or argue with their loved ones, members of the healthcare
team, and question their faith beliefs (Singer, 2018). Patients may think that they will be able to
overcome their diagnosis by arguing, and when they realize this is not the case, they can become
depressed and have feelings of guilt and helplessness (Singer, 2018).
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According to Heussner (2016), anger is a coping strategy explained by the unfairness of
the fate that a person faces when they have a threatening illness. Heussner claims that it is more
difficult to blame fate than to hold the physicians accountable for a diagnosis. Patients will often
react with ‘why me?’ and become angry at the thought of having their future taken away from
them (Heussner, 2016). These ruminations often lead to a sense of panic where patients think that
there is not enough time to get their affairs in order or carry out certain desires, which usually
casts a temporary anxiety (Kübler-Ross, 1974).
Bargaining
In the bargaining stage, patients often aim their pleading towards God or their faith,
while others choose to involve their family or friends. Patients will bargain with God and plead
to extend their life, make promises of good behavior, or make a religious dedication in order to
be spared from their suffering (Kübler-Ross, 1974). Patients report feeling they know there is a
slim chance of God answering their pleas but hope to be rewarded for their good behavior and
religious dedication. Prayers may not always involve extending life or miraculous healing, but
can be as simple as getting through a day without pain or difficulties (Kübler-Ross, 1969).
Commonly, patients will bargain for more time in order to attend a big event, such as a child’s
wedding or a specific holiday. Patients presume their reward for good behavior should be
surviving long enough to attend that particular event (Kübler-Ross, 1969).
Depression
The depression stage may begin with patients mourning past losses before losing interest
in everything happening around them. Often in this phase, the patient will not want to socialize
with people and will lose interest in objects or activities they once cared about (Kübler-Ross,
1974). Depression symptoms are common among patients with a new diagnosis of cancer and
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can affect a patient’s quality of life. Depression can amplify some of the physical characteristics
that are involved with having cancer like pain, fatigue, loss of appetite, and quality of sleep
(McKee & Kelley, 2020). According to one article, depression can cause a person to feel
hopeless and experience a lack of joy (Berry, 2018). Sleep may be interrupted and food either
acts as a comfort or is unappetizing (Berry, 2018). Lastly, self-esteem is often absent and
concentration may be hard to achieve during this phase (Berry, 2018).
Acceptance
When a patient is given enough time to go through the denial, anger, bargaining, and
depression stages, they hopefully reach the acceptance stage of their diagnosis. Most become
comfortable with sharing their diagnosis with people they know and love, and they are able to
talk about cancer without associating the aforementioned feelings (Kübler-Ross, 1969).
Acceptance should not be confused with happiness (Kübler-Ross, 1969). A patient who has
accepted their diagnosis is not necessarily happy about it, but eventually comes to realize that
cancer is a part of their life forever, whether they go into remission or not (Kübler-Ross, 1969).
One thing that tends to be present through all stages of grief is hope. Hope is to “want
something to happen or be true” (Merriam-Webster, n.d., Definition 1.g). When hope is present,
the thought of a challenging situation, like a cancer diagnosis, can help sustain a patient through
a period of suffering (Kübler-Ross, 1969). Hope is a sense of “rationalization for [certain
patient’s] suffering, and for others, it remains a form of temporary but needed denial”
(Kübler-Ross, 1969, p. 134). Once a patient stops showing signs of hope, it could be an
indication that they have given up on any thought of a possible cure, recovery, or survival
(Kübler-Ross, 1969). The ultimate goal of the five stages of grief is for patients to come to the
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realization that cancer does not define them; it is merely something that is happening to them
(Kübler-Ross, 1969).
Steps After Getting Diagnosed
Getting a Second Opinion
Getting a second opinion may be a desired option for some patients, while others may
find it unnecessary. Second opinions can be affirming to a patient who has a new cancer
diagnosis and may be an option that some feel they need to explore before beginning treatment
(American Cancer Society, 2019a). One reason to get a second opinion includes verifying the
pathology of the biopsy to confirm the cell type of the neoplasm. Confirming the pathology will
help the medical team tailor the most precise treatment plan for the cell type. A second opinion
may also be worth obtaining to give “reassurance for diagnosis [and] confirm treatment and
prognosis” (Peier-Ruser & von Greyerz, 2018, para. 2). However, others may feel this is not
necessary as they have established an agreed upon treatment plan and have built a relationship
with their care team.
According to one study, there are some common factors that have been identified as
obstacles that keep patients from seeking another opinion (Peier-Ruser & von Greyerz, 2018).
First is the state of emotional shock someone goes through when first diagnosed with cancer.
Once the word ‘cancer’ is heard, patients may tune out information that is given at the time of
diagnosis. In addition, patients can have immediate fears and concerns about the state of their
future, which contributes to their emotional state at time of diagnosis (Peier-Ruser & von
Greyerz, 2018). The recommendations for urgent treatment initiation by the care team and
caregivers may cause the patient to feel pressured to start a regimen and forgo a desired second
opinion (Peier-Ruser & von Greyerz, 2018). Another factor is the difficulty of getting an
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appointment with a specialist on short notice, as appointments may not be available for weeks or
months, which could delay treatment. During this process of diagnosis, patients can be
overwhelmed with the amount of information they receive, making them hesitant to see another
specialist (Peier-Ruser & von Greyerz, 2018). Lastly, patients have noted a fear of compromising
the patient-physician relationship (Peier-Ruser & von Greyerz, 2018). Patients do not want to
offend their physician by getting a second opinion and jeopardize the established relationship
with the diagnosing medical provider (Peier-Ruser & von Greyerz, 2018).
Advanced Care Planning and Directives
Advanced care planning is a decision-making process that often occurs after a diagnosis,
learning of an ill-fated prognosis, or near end-of-life, and defines a patient’s wishes and medical
preferences in the event they are no longer able to make their own decisions (Conner, 2020). The
Institute of Medicine’s report Dying in America defines advanced care planning as “a process for
setting goals and plans with respect to medical treatment and other clinical considerations. It
brings together patients, families, and clinicians to develop a coherent care plan that meets the
patients’ goals, values, and preferences. It can begin at any point in a person’s life, regardless of
his or her current health state; is revisited periodically; and becomes more specific as changing
health status warrants” (Sudore et al., 2017, Delphi Methods section). The advanced care plan
should be initiated early in a diagnosis and completed while the patient still has cognitive
function in order for the documents to be legally recognized (Conner, 2020). Advanced care
planning is important to put into place early, so that in the event the patient is no longer able to
express their wishes or speak for themselves, a document is already in place stating those wishes.
If there is no such document at the time a patient can no longer speak for themselves, family is
often left to make medical decisions, which may or may not align with the patient’s wishes. The

39
document should state the overall goals of the patient in regards to their medical care and assign
someone to speak for them in the event they cannot do so. There are several legal documents
involved when establishing advanced care directives, and patients should obtain these documents
from their provider or care coordinator (Sudore et al., 2017).
An advanced care directive is a document that defines a patient’s desires and specific
treatment wishes, which are kept on hand by their medical team and referred to when needed
during the course of treatment. This document may be changed at any point during the patient’s
treatment course and addresses resuscitation and life support wishes, pain management, and
specific treatment goals (Silveira, 2020). A healthcare power of attorney (HCPOA), also known
as a healthcare proxy, or a durable medical power of attorney (DPOA) is designated by the
patient to make medical decisions on their behalf in the event they are unable to make their own
decisions (Conner, 2020). Refusal of treatment orders include a do-not-resuscitate (DNR), a
do-not-hospitalize (DNH), and a do-not-intubate (DNI) order. A DNR is a statement preventing
unwanted cardiopulmonary resuscitation (CPR) in the event a patient’s heart stops beating and/or
they stop breathing. This document protects the patient from unwanted lifesaving measures such
as chest compressions, rescue breathing, defibrillation, and advanced cardiovascular life support
in order to allow for a natural death (Conner, 2020). A DNH expresses a patient’s wish to avoid
hospitalization under specified circumstances in an effort to limit the number of hospital
admissions in hopes of increased quality of life (Conner, 2020). A DNI states that if a patient
stops breathing, they do not wish to be intubated or put onto a mechanical ventilator. In this
instance, other measures like CPR or defibrillation can be utilized to get the heart pumping
again, but no form of assisted respiratory effort can be attempted (Conner, 2020).
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Coping Strategies
Receiving a new cancer diagnosis is an emotionally overwhelming experience in the life
of a patient (Taylor et al., 1986). Due to the nature of a cancer diagnosis, it is a continuous
physical and psychological stressor in a patient’s life. Having social support from others who are
also experiencing cancer, outside of family and friends, can be reassuring (Taylor et al., 1986).
One way to achieve this sense of community is through support groups or patient advocacy
groups. A support group involves people undergoing a similar situation that may interact through
organized therapy, social events, virtual meetings, etc. There is an emphasis on providing support
through participation and discussion of shared feelings, emotions, or any other topic. Attendance
is voluntary and the purpose of the group meetings are to provide social support and help patients
cope with their illness (Taylor et al., 1986). This social support includes emotional support
provided by other patients experiencing similar situations (Taylor et al., 1986). Rein in Sarcoma
is an organization that provides patient advocacy through events that are offered to sarcoma
patients, survivors, caregivers, family members, and friends. Activities include regularly
scheduled small group meetings for survivors, patients, and caregivers, the annual Party in the
Park fundraiser, and numerous other fundraising and silent auction events held yearly to support
sarcoma patients, education, and research (RIS, 2020).
Support of a Newly Diagnosed Cancer Patient
A new cancer diagnosis has been described as an overwhelming, scary, and emotional
event for the patient and their family members. In one study, family members reported feeling
unsupported and had several concerns during their loved one’s cancer journey (Dionne-Odom et
al., 2019). The most significant concerns reported were managing stress, dealing with fatigue,
worrying about the future, talking about emotions, and finding financial help (Dionne-Odom et
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al., 2019). Cancer is sometimes referred to as a ‘family disease’ because it can cause significant
strain and bring about new and unexpected lifestyle changes for family members (Coyne et al.,
2020). The journey after a cancer diagnosis can be long, depending on the type of cancer,
prognosis, or treatment plan. The average active treatment phase is 14-24 months, and even
when treatment is successful, there is often a need for family and caregiver support for months
and/or years after (Coyne et al., 2020). Family members and caregivers often help their loved
ones get to various appointments, prepare meals, provide housekeeping tasks, and provide
physical and emotional support (Nipp et al., 2016).
Caring for someone with cancer is not an easy task, especially with the uncertainty that
comes with cancer. Nipp et al. (2016) found that family members and caregivers who offer a
great deal of support for their loved ones have been known to suffer significant adverse health
consequences themselves. Family members, caregivers, and the patient can equally suffer from
depression, anxiety, physical changes, reduced socializing, and a diminished quality of life
(Coyne et al., 2020). Family members and caregivers need to remember to address their own
physical and mental health needs. The American Cancer Society (2020a) has several
recommendations for self-care, such as eating healthy, reducing alcohol and tobacco use,
exercise, finding time to focus on oneself, and reaching out to medical professionals or therapists
if needed. When caregivers have social support, it has been shown that their own stress and
burden are decreased (American Cancer Society (2020a). Taking a short break throughout the
day or utilizing respite care to provide temporary relief of duties can also be used as caregiver
self-care. Caregivers need short periods of rest and relief to stay emotionally and physically
capable of their caregiving duties (American Cancer Society (2020a).

42
Family members and caregivers of newly diagnosed patients may not know what to
expect or be prepared in regards to physical and mental changes their loved ones may
experience. Cancer patients can experience hair loss, weight loss, nausea, vomiting, pale skin,
and fatigue (American Cancer Society, 2016). A patient may experience a wide range of
emotions, including sadness, anger, fear, uncertainty, and mood swings (American Cancer
Society, 2016). Family and caregivers need to understand that it is normal for their loved one’s
emotions to fluctuate and it is part of the grieving process while going through cancer (American
Cancer Society, 2016).
How to Talk With a Cancer Patient
After a patient’s new cancer diagnosis, it is not uncommon for family and caregivers to
feel uncomfortable around the patient or not know how to talk to them. A loved one’s cancer
diagnosis “often reminds us of our own mortality” (American Cancer Society, 2016, “How Do I
Get Over Feeling” section). If a family member or caregiver feels uncomfortable or guilty
because they are healthy, it is important to realize that this response is normal. To help overcome
these feelings or fears, the American Cancer Society (2020a) recommends frequent
communication. Specifically, family members and caregivers should talk about what makes them
frightened or uncomfortable with the person who has cancer. Despite this, it is reported to be
difficult to talk to a loved-one with cancer because they are afraid to say the wrong thing. In
addition, one of the most important aspects of communication is listening. Caregivers and family
members should hear what their loved one is saying, try to understand what they are saying, and
put their own feelings and fears aside (American Cancer Society, 2020a).
When speaking with cancer patients, family and friends should try to avoid common
phrases like ‘I know how you feel’ or phrases about their appearance like ‘You are looking pale’
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(American Cancer Society, 2020a). Unless a family member or caregiver has experienced the
exact situation, they cannot truly understand what their loved one is experiencing. Instead, family
and caregivers should take their cues from their loved one and let the patient guide the
conversation, respect treatment decisions they have made, and keep their relationship as normal
and balanced as possible (American Cancer Society, 2020a). During this time, patience and
compassion may be called upon more frequently.
Conclusion
An early sarcoma diagnosis is imperative as this cancer is highly metastatic and is
associated with a high mortality rate. Proper patient education at an appropriate health literacy
level may improve quality of life, adherence to treatment plans, and improve outcomes. Also, it
is helpful to educate patients on the stages of grief and associated emotions that come with a
sarcoma diagnosis. Teaching healthy coping techniques and providing support services may
improve outcomes and can be utilized during treatment courses. In addition, family and caregiver
support is an important factor that plays into the emotional well-being of the patient. It is
necessary that caregivers and family members also utilize support services and take care of
themselves during a cancer diagnosis.
Chapter three will discuss the methodology utilized in creating the five educational
videos aimed toward newly diagnosed sarcoma patients and their families, which are available
on Rein in Sarcoma’s website and YouTube channel.
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Chapter 3: Methodology
Introduction
Chapter three describes the methodology that the authors used in this community service
project to create five videos for the RIS YouTube channel. This chapter discusses the rationale
for the project, the intended audience that the videos impact, along with the project details, tools,
and a discussion of project barriers.
The intention of this project was to partner with RIS to create videos that are informative,
supportive, and provide hope for newly diagnosed sarcoma patients and families at a health
literacy level that is appropriate for the general public. A sarcoma diagnosis can often be
unexpected and overwhelming for patients and families. These videos provided RIS with an
additional patient education tool that the organization can provide to newly diagnosed sarcoma
patients in conjunction with the materials they currently provide to patients.
Rationale for Project
Rein in Sarcoma was founded by Karen Wycoff in 2001 and is now the largest sarcoma
foundation in the Midwest with recent national and global outreach. Rein in Sarcoma provides
support to any sarcoma patient, survivor, and family member who accesses their organization;
however, their primary target audience are residents of Minnesota, Iowa, North and South
Dakota, and Wisconsin (RIS, 2020). They also provide information to improve sarcoma
education among the general public and healthcare providers using their website, YouTube
channel, and social media. Rein in Sarcoma’s mission is “dedicated to educating the public and
medical community about sarcomas, supporting sarcoma patients and their loved ones, and
funding research directed toward developing new treatments and finding a cure for sarcoma
cancers” (RIS, 2020, Our Mission section). Rein in Sarcoma raises and provides funding and
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maintains partnerships with the University of Minnesota, the Mayo Clinic, and Children’s
Minnesota to support and enhance sarcoma research.
Rein in Sarcoma was looking to expand their education materials to include informational
and supplemental videos for newly diagnosed sarcoma patients and family members, which can
be used in conjunction with the RIS patient guidebook that is given to patients at time of a new
sarcoma diagnosis. Patient education is essential after receiving a new cancer diagnosis. Proper
patient education increases both the patient’s and family’s quality of life (Giuliani et al., 2020). It
is commonly reported that cancer patients do not understand the information given by medical
providers after a new cancer diagnosis. Two main factors contribute to this misunderstanding:
low health literacy and the emotional process that may leave patients feeling overwhelmed and
stressed after a cancer diagnosis (Giuliani et al., 2020).
The authors volunteered their services in this community service project by providing
research, medical knowledge, and devoted time in the creation and production of the five
educational videos. The intended goal of the five videos was to improve access and patient
education for newly diagnosed patients and families at an appropriate health literacy level, with
the hope of reducing negative emotional aspects that accompany a new diagnosis.
Population
The intended target population for this community service project is broad and consists of
current sarcoma patients, previously diagnosed patients, individuals in remission, family
members, caregivers, and acquaintances of sarcoma patients. Although this project is aimed
towards newly diagnosed sarcoma patients, caregivers, and family members, anyone who
accesses the RIS YouTube channel can utilize these five videos. For this project, the authors
worked with RIS executive director, Janelle Calhoun, and education and communication
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manager, Katy Engelby. Alan Christensen, a volunteer videographer and sarcoma caregiver
emeritus, recorded the videos. The RIS board members approved a budget to assist in
professional video editing before they were given to RIS to post.
Project Plan and Implementation
To fulfill the need of expanding and improving access to quality sarcoma education, RIS
and the authors collaborated with volunteers, which included educators, sarcoma specific
medical and treatment providers, sarcoma survivors, and caregivers. Rein in Sarcoma and the
authors approached the volunteers to ensure their desire to participate in this community service
project and obtained consent via a volunteer waiver through RIS. The volunteers in return
provided personal testimony and public education through participation in the five videos that
were subsequently uploaded to the RIS YouTube channel and premiered at the 2022 annual
American Society of Clinical Oncology (ASCO) conference. Through collaboration and
discussion between the authors and RIS, the five video topics were selected. The aim of the
selected topics were to cover frequently addressed questions or concerns of newly diagnosed
sarcoma patients. The videos were then presented in such a way that were designed to inform,
educate, and encourage patients and caregivers.
During the early stages of planning, the authors met virtually with each volunteer video
participant where talking points and topics for each video were discussed and decided upon
collaboratively. The authors acknowledged that the volunteers contributed and incorporated their
own ideas or topics into the talking points. Janelle Calhoun and Katy Engelby of RIS provided
final approval of the talking points and topics prior to initiating filming of the videos. The
volunteers were provided the option of filming in person or remotely due to the
immunocompromised status of a few of our volunteers combined with the fact that this
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community service project was initiated in 2020 during the COVID-19 pandemic. The authors
maintained adherence to all state laws and COVID-19 regulations during video production,
which included reducing participant numbers, wearing masks, and enforcing social distancing
guidelines.
Video number one provides an overview of sarcoma that features an orthopedic surgeon
who specializes in surgical treatment of sarcoma. The aim of this video was to educate viewers
after a new sarcoma diagnosis in hopes of demystifying the concept of sarcoma and elaborating
on its definition. Specifically, the aim was to break down major subtypes and address common
questions patients often ask about the formation of sarcoma. The second video gives an overview
of sarcoma treatment and features a hematology/oncology physician assistant who discusses
chemotherapy treatment of sarcoma. He also addresses side effects, symptom management, and
self-care through the process of chemotherapy. Next, a radiation oncologist demystifies the
concept of sarcoma treatment via radiation. Radiation is not generally well understood by the
public, so the education provided by the radiation oncologist addressed topics such as delivery of
radiation, side effects, and timeline of treatment. Lastly, a sarcoma surgeon discussed the surgical
treatment of sarcoma, which is the mainstay treatment course for both STS and osteosarcoma.
The surgeon discussed risks and benefits of surgical excision, amputation, and limb-salvage
along with the average timeline and follow up.
The third video featured sarcoma survivor testimony from three RIS volunteers whose
experiences include differing stages of treatment and remission. The goal of this video was to
provide hope and support to patients and caregivers through survivor experiences that are
relatable and provide insight into the process when receiving a new sarcoma diagnosis. The first
participant featured is a fifteen year fibrosarcoma survivor who discussed her story starting with
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recognition of her lump via her hairdresser, her initial diagnosis and journey, as well as self-care
and what life looks like post-diagnosis and surviving sarcoma. The second participant featured in
this video is a myxoid sarcoma survivor who, at the time of this publication, was still undergoing
surgical reconstruction to improve functionality of her hand. She addressed what life was like
during her treatment and gave advice to those who may be going through a similar journey. The
third participant is a rhabdomyosarcoma survivor who is five years out and still has no evidence
of disease. He discusses his journey through initially feeling unwell, to sarcoma diagnosis, and
through his treatment experience. He also gave his perspective of the five stages of grief and
provided advice on the importance of self-care.
The fourth video addressed the experience and importance of the caregiver’s journey
after a sarcoma diagnosis. This was achieved through personal testimony of volunteers that
provided perspectives from a mother/caregiver whose daughter is currently disease-free from
sarcoma and two other perspectives from a male and female spouse/caregiver who’s loved ones
have since passed away from sarcoma. The goal of this video was to provide education and
support for caregivers with the aim of normalizing what often feels like an isolating experience.
Video five is an educational tool that aimed to address advanced care directives and
featured a physician assistant educator and an end-of-life doula/sarcoma caregiver. The aim of
this video was to explain terminology and elaborate on topics that may not be well understood by
patients, such as advance care planning, durable power of attorney, palliative care, and hospice.
Other relevant topics addressed were obtaining a second opinion, the five stages of grief, and
alternative support services for patients and caregivers who are experiencing a sarcoma
diagnosis.
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The videos were filmed by a volunteer videographer from RIS, Alan Christensen, who
provided his personal filming equipment, which included but not limited to iPhones staged from
differing angles, stands, personal microphones, and lighting equipment. Filming for all five
videos were done at the Bethel University Anderson Center common areas and at the University
of Minnesota. During filming, the authors observed and directed off view of the camera and
conversed with each volunteer participant through an interview style where the author proposed
a topic or question and the participant responded. The aim was for responses to flow with an
appearance of ease as one would see during a conversation. Filming was completed over a course
of eight months from October 2021 to May 2022.
Upon the completion of filming, the raw video footage was sent to be formally edited by
Northern Lights Video, Inc., a local Minnesota-based editing company. Rein in Sarcoma has
utilized the services of Northern Lights Video for prior projects and it was the preference of the
organization to use their services for this project. Funding for the editing of this project was
generously donated by RIS. The editing process took approximately four months and required
frequent virtual collaboration between the authors and the editor. The video footage was
condensed, organized, and music, graphics, and photos were added to produce the final project.
The authors then approved the final edits of the videos. The videos were sent from the editor to
RIS where they were then uploaded onto the RIS YouTube channel and webpage. The videos
were assigned to a QR code, which was printed on cardstock and detailed the project videos. The
QR codes were handed out and presented at the 2022 ASCO conference in Chicago to a global
audience of medical providers.
When starting a community service project it is important to consider the ethical
implications associated with the project, which includes consideration of the sarcoma patient and
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their healthcare team. An ethical implication of this community service project that was
acknowledged was that the information presented in the five videos may not be representative of
the viewer’s precise healthcare team opinions or current treatment regimen. To address this issue,
a statement was displayed at the beginning of each of the five videos that stated “Every
individual’s medical situation, sarcoma experience, and recovery is unique. Always consult with
your own medical team or personal physician about your situation. The information presented in
this video is not intended to replace and should not replace a physician’s medical judgment or
advice”. The author's goal during the creation and implementation of this project was to protect
the integrity of shared medical decision making and the members of the sarcoma healthcare
team. This was achieved through careful consideration of the narrative of this paper, specifically
avoiding word usage or ideas that may be offensive or controversial. This reinforced our project
goal by encouraging healthy communication and trust in the relationship between the sarcoma
patient and their healthcare team.
Project Tool
The project tool created for this project consisted of five videos aimed to enhance
sarcoma education by providing an educational resource at an appropriate health literacy level,
enhancing access to education via the remote delivery of the videos online, and provide support
and hope to newly diagnosed sarcoma patients and caregivers. The tool consists of five videos,
which remain under 60 minutes in length to avoid loss of interest, but may be paused and
resumed at the viewer’s convenience. This hopefully allows for increased information
comprehension and by delivering the videos through YouTube, subtitles may be added to
enhance learning. The videos covered important topics in sarcoma including: a sarcoma
overview, overview of sarcoma treatment options, survivor stories, caregiver experiences, and
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education on advanced care planning, coping, support services, and the five stages of grief. The
video participants discussed their personal sarcoma experiences and gave advice to newly
diagnosed sarcoma patients. The original talking points for each of the five videos are located in
Appendix B of this paper. Upon completion of the project, the project tool consists of five videos
that were sent directly to RIS from the editor. The videos were reviewed, approved, and uploaded
by RIS to their YouTube channel and website, and attached to a QR code that was distributed to
oncology professionals at the 2022 ASCO conference.
Barriers to the Project
During this community service project, there were barriers that the authors had to
overcome. This project was initiated during the COVID-19 pandemic in 2020, which created a
barrier to the filming of the project. Throughout the majority of the project, the COVID-19 case
rate in the Twin Cities and morbidity and mortality burden was high. The video participants
consisted of a few immunocompromised volunteers, which required careful consideration and
planning. Throughout the filming of this project, there were several filming delays due to
COVID-19 illness from either volunteer participants or authors. Despite this barrier, the video
participants were able to be filmed in person for all five videos. A second barrier to the
completion of this project was the difficulty in coordinating schedules of the many contributors
to this project. The authors were creating this project during their physician assistant master's
program, which consisted of full-time classroom based learning and traveling out-of-state to
complete clinical rotations. The project relied on the availability of the videographer's equipment
and utilization of his expertise during the filming. Also, coordination of filming the videos was
dependent on the availability of the videographer, participant, and authors.
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Conclusion
Through literature review by the authors and collaboration through RIS, a need was
identified to provide support and hope, expand access, and enhance health literacy through
creating educational information for newly diagnosed sarcoma patients and their caregiver. In
addressing existing barriers during the start of the project, such as the COVID-19 pandemic, the
project tool was established as a series of five videos that would accompany patient advocacy
materials that RIS currently use such as the patient guidebook. The five videos may provide
viewers with access to sarcoma education and support through the experiences of medical
providers, educators, survivors, and caregivers. Overall, this may enhance patient health literacy
and allow for improved engagement in treatment and medical decision making while increasing
quality of life through reduction of emotional trauma after a new sarcoma diagnosis. Chapter
four will discuss the project outcome, the project’s limitations, and discussion on how this
project may be expanded in the future by RIS or through further volunteer contributions.
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Chapter 4: Discussion
Introduction
With the support and guidance from RIS, this community service project was created to
expand access to sarcoma education and enhance health literacy by adding to existing RIS
educational materials such as the sarcoma patient guidebook. This chapter discusses all aspects
of this community service project, including author review of the foundational and new literature
from chapter two, project creation and implementation, and lastly will summarize the outcome of
the project. Also discussed are the limitations that were encountered during the project and
concludes with a discussion of possible enhancements to how this project can be expanded in the
future.
Summary of Results
Rein in Sarcoma was looking to expand educational videos aimed towards newly
diagnosed sarcoma patients and their family members. During the literature review, a need was
identified that patients may not have access to educational material with an appropriate health
literacy level after a diagnosis of sarcoma. Education given at the time of diagnosis is imperative
for patients as this enhances their cooperation in the treatment process, quality of life, and overall
patient outcomes. An emotional burden and associated trauma exists after a diagnosis of
sarcoma, and information presented at this time is subject to distortion and misunderstanding.
Patients “find that [they] can only take in small amounts of information [and] need to have the
same information repeated to [them]” (Cancer Research UK, 2017, Shock and Denial section).
One specific study found when looking at online sources of sarcoma education, that the
overwhelming majority is written at or above an eleventh-grade reading level (Patel et al., 2015).
The project goals were to expand patient sarcoma education that is accessible remotely. With
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careful consideration, the videos were created to more closely match the general population's
average health literacy at a reading level of seventh grade and below. Upon filming completion,
the five videos were provided to RIS. Rein in Sarcoma posted each individual video to their
YouTube channel, website, and produced QR code handouts that were distributed at the 2022
ASCO conference providing easy access to the online videos.
The topics for the five videos produced attempted to address commonly raised questions
and concerns of newly diagnosed sarcoma patients, families, and caregivers. The topics for each
video were decided upon during review of sarcoma literature and by collaboration of the authors,
RIS, and video participants. Rein in Sarcoma provided volunteers who shared experiences and
expertise of their sarcoma journey.
In addition, a videographer/sarcoma caregiver volunteered to film this project, which was
successfully produced using the videographer’s personal filming equipment. The five videos
were filmed at two separate locations: Bethel University Anderson Center and the University of
Minnesota. Upon completion of filming, the footage was sent electronically to Northern Lights
Video, Inc., for professional editing.
The final edits were approved by the authors before the videos were sent directly to RIS
for final approval. Rein in Sarcoma subsequently uploaded the videos to their website and
YouTube channel where viewers can utilize the closed captioning option if language barriers
exist. Viewers can also pause the videos as needed if they are unable to complete the video in its
entirety or need breaks for comprehension. This delivery improves the accessibility of the
material for non-English speaking patients and families, which was a common question
professionals asked the author at ASCO. The videos were also assigned to a QR code and printed
on handouts that will accompany the patient guidebook when given to patients with a new
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sarcoma diagnosis. The QR code handouts, which provide direct access to all five videos, were
distributed to a global audience of oncology professionals at the 2022 ASCO conference in
Chicago.
A major barrier to the completion of this project was the COVID-19 pandemic. To
minimize disturbances in the project, the authors followed all COVID-19 precautions as
suggested by the state of Minnesota, such as limiting the number of participants allowed in the
filming space, wearing facemasks, and remaining socially distanced. In addition, film scheduling
was made difficult due to unforeseen illnesses, cancellations, and scheduling conflicts between
the authors, videographer, and video participants.
It is difficult to assess the outcome and effectiveness of the five videos at this time of
publication. This is largely due to time constraints, which include a short timeline from when the
videos were debuted online in June 2022 to the authors completion of this community service
project in July 2022. This does not allow for the opportunity of the authors to receive direct
feedback or distribute surveys that may analyze the effectiveness of the project tool. In the
future, RIS may choose to collect feedback via the participants, online viewers, track the number
of views of each video, or read viewer comments, which may indicate viewer reception to this
project and its effectiveness. In the future, RIS can use this project and materials to further
expand or update the video series. There is also a plethora of unused video footage, which allows
for future opportunities to repurpose the video into creation of educational videos.
Limitations
Limitations of this project were identified and acknowledged after its completion. After
filming, the authors discovered that the video participants were composed of a population of
primarily females, Caucasians, those with higher educational achievements, and middle to upper
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class privileges. The authors acknowledge that a sarcoma diagnosis impacts people of all ages,
races, genders, education levels, and socioeconomic backgrounds. In the future, the limitations to
this project may be overcome by expanding and incorporating a population of sarcoma patients
and caregivers more inclusive of different identities, races, ethnicities, educational backgrounds,
and income levels into the video series.
Another limitation to this video series is that the videos are presented in an English
option only, which limits the targeted audience by decreasing accessibility to non-English
speakers. To circumvent this, authors recommend watching the videos on YouTube and utilizing
closed captioning options, which may allow for reading and comprehension in one’s native
language.
There is a resource limitation to this project as the videos are only accessible virtually
and require viewers to have personal or public access to the internet, computer, cell phone, or
other viewing device, and be able to access the RIS website or YouTube. Additionally, to benefit
from the five videos, viewers must know the videos exist, and this may happen by direct word of
mouth, association with RIS, or through the Bethel University Physician Assistant program.
Further Projects
After the completion of the five videos for newly diagnosed sarcoma patients, the authors
released all materials including videos, talking points, and all raw footage to RIS. In the future, if
RIS desires to expand or update this community service project, they have access to and may use
all resources above. This may be done through RIS directly or possibly through future Bethel
physician assistant student volunteers for RIS. The authors identified a limitation to the current
series as a lack of inclusivity, and suggested as a possible future project expansion, a video that
addresses cultural elements of racial and ethnic diversity that may contribute to sarcoma

57
diagnosis and care. Additionally, it would be recommended to create a video with equal
representation and identification of the sarcoma journey from different perspectives of gender
and identity.
Lastly, a future project expansion may want to collect feedback from viewers or a cohort
of sarcoma patients and caregivers after watching the five videos. The video series could then be
expanded based on specific feedback received by the participants.
Conclusion
Sarcoma is a connective tissue neoplasm that, due to its intrinsic characteristics of
formation, is a cancer that is often accompanied with delayed diagnosis, misdiagnosis, and
requiring specific biopsy technique to prevent metastasis. Early detection and diagnosis is vital
for all cancer types, but particularly in cancers like sarcoma, which have a heavy metastatic
disease burden due to the ease of lymphatic and vascular metastasis.
During the literature review of this community service project, the authors discovered a
need to expand sarcoma education through improvement of remote access and by matching
viewer health literacy, with the goal to improve patient cooperation, engagement in care, quality
of life, and patient outcomes. A retrospective study by Patel et al. (2015) that the authors discuss
in chapter two shows that the majority of online sarcoma education utilized by patients and
caregivers is written above an eleventh grade reading level, which is far above what the NIH has
established as the reading level of the general US population. After the literature review and
subsequent identification of this disparity in the sarcoma population, there was a responsibility
by the authors during the creation of this project to decrease this health literacy gap. The authors
believe this was accomplished by the successful completion of the five videos that improve
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health literacy through education presented via experiences of participants and educators that is
easily accessible in an online format.
In collaboration with RIS, the authors produced five videos that gave an overview of
sarcoma, standard treatment options, sarcoma survivor testimonies, the impact of sarcoma
through personal testimonies of caregivers, and an overview of advance care planning. At the
time of publication, all five videos are currently available for viewing on the RIS website and
YouTube channel. Despite being unable to directly assess the effectiveness of the videos due to
the constraint of limited time availability that the videos have been online, the authors are
hopeful that the overall takeaway from the videos will provide support and hope, all while
helping to relieve patient and caregivers fears and anxiety that accompany unknowns with a new
sarcoma diagnosis.
Throughout this community service project, the authors expanded their skill set,
knowledge of oncology concepts, sarcoma specific literature, and patient care through an
extensive literature review, composition of this thesis paper, designing and creating the five
videos, and the collaboration with survivors, caregivers, medical professionals, and educators.
The importance of early sarcoma diagnosis and patient accessibility to appropriate literacy level
education materials that accompany one-on-one provider teaching cannot be emphasized enough.
Newly diagnosed sarcoma patients encounter a heavy emotional burden due to the inherent
nature of sarcomas and associated prognoses. The authors’ hope that this video series will be
utilized by sarcoma patients and caregivers as an educational tool that may assist in providing
hope and support. Secondly, the authors hope that healthcare professionals with access to this
community service project will recommend the five videos to newly diagnosed sarcoma patients,
family, and caregivers as a supplement to the one-on-one education they provide alongside the
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RIS patient guidebook, which may assist in comprehension, participation of diagnosis and
treatment plans, improve patient outcomes, and quality of life.
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1/6/2020

Dear Bethel Physician Assistant Program,
On behalf of the 501c3, Rein in Sarcoma we, Executive Director, Janelle
Calhoun and Manager of Sarcoma Education and Communications, Katy
Engelby, give permission for students Jennifer Gribble, Jaclyn Robles and
Taylor Schreier to work on behalf of our community through their sarcoma education
project. We will support them with connections to sarcoma experts at the University
of Minnesota, Mayo Clinic and HealthPartners in addition to connecting them with
sarcoma patients or other helpful resources. We are thankful for the opportunity to
work with these students and increase sarcoma education. Please contact either Katy
Engelby, or me with any needs or concerns around the students and their work.
In mission,

Janelle
Janelle Calhoun
Executive Director
Rein In Sarcoma
7401 Central Avenue NE
Fridley, MN 55432
Office: 763-205-1467
Cell: 651-341-4150
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APPENDIX B
Video Scripts
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Video one will focus on an overview of sarcoma and will be fifteen to twenty minutes in
length. It will highlight one physician who works primarily in the sarcoma field. The beginning
of the video will be an introduction of the provider, followed by an overview of sarcoma
etiology, clinical presentation, diagnosis, and brief treatment overview.
The following questions will be included in the script:
● How do you come up with a treatment plan?
● How does someone get sarcoma?
● How is someone diagnosed? What is involved with getting a biopsy, what imaging should
the patient expect?
● What is sarcoma? What are some of the signs and symptoms that people have when they
come to see you?
● What is the remission process?
● What is your advice to newly diagnosed patients or what do you feel is the most
important thing for them to know?
● Who gets sarcoma? Age group, ethnicities, genetics?
● Who makes up the medical team?
Video two will be a thirty to forty-minute montage of three different sarcoma experts,
which will include an oncological surgeon, a radiation oncologist, and a hematologist/oncologist
physician assistant. The purpose of this video will be to highlight their expertise, talk about
common pathways for sarcoma treatment, and highlight any new treatment options.
The script will include the following questions:
● Do you see a difference in patient outcome when patients have a close support system?
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● How do you build a trusting relationship with the patient?
● How is sarcoma staged (general/basic overview) and how does that guide you when
coming up with a treatment plan?
● If chemotherapy is needed, who gets it and why, how do patients prepare for
chemotherapy, and what are the risks, benefits, side effects that go along with
chemotherapy?
● If radiation is needed, who gets it and why, how do patients prepare for radiation and
what are the risks, benefits, side effects, and cost?
● If surgery is indicated, what is done to prepare for the procedure, how do you choose
limb salvage or amputation, and what are other considerations you tell patients about?
● What are common imaging options used? (ex: PET scan, MRI, CT)
● What are your thoughts on sarcoma clinical trials?
● What do you want patients to know about radiation, chemotherapy, surgical, etc. before
they start treatment and what is involved with each? How long, what is the recovery like,
side effects, etc.?
● What is your message to newly diagnosed patients and do you have anything you want
patients to know?
Video three will focus on sarcoma survivors and the experience they had when they were
first diagnosed with their specific type of sarcoma. This video will be twenty to thirty minutes in
length and will feature up to three different people who have been diagnosed with sarcoma. The
beginning of the video will be an introduction by the survivor where they will tell their story and
personal experiences with sarcoma. The end of the video will be the sarcoma survivor’s thoughts
and suggestions for newly diagnosed sarcoma patients.
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The script will include the following questions:
● Did you get diagnosed quickly or was there some time before it was decided that you had
sarcoma?
● Did you go through the stages of grief?
● Did you have a good support system around you who helped you get through this?
● Have you ever heard of this kind of cancer or did you know what it was?
● What advice would you give to a newly diagnosed sarcoma patient?
● What was the treatment like for you?
● What was your first thought when you were told you have cancer?
Video four will highlight family members/caregivers of someone that has had sarcoma.
The video will be twenty-thirty minutes in length and feature up to three people who have had a
loved one go through sarcoma highlighting various viewpoints of a spouse, parent, and child.
The beginning of the video will be an introduction by the caregiver, they will tell the story of
their loved one and may include a discussion of the stages of grief they went through or will
include a social worker who discusses the stages of grief and what that looks like in both patient
and caregiver.
The following questions will be included in the script:
● Did you get involved with any organizations or outside support groups?
● Did you utilize other support groups?
● How did you find support while helping your loved one through cancer?
● How did you offer support during their sarcoma journey?
● How did you yourself get support or what helped you get through this difficult time?
● Social worker: What are the stages of grief? Is this normal? Any suggestions for getting
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through these stages? How can family members help get their loved ones through these
stages?
● What advice would you give to other families who are going through this difficult time?
● What went through your mind or how did you feel when you first learned they had
sarcoma?
Video five will focus on advanced planning that many patients may have to face once
they have been diagnosed with cancer. The video will be twenty minutes in length and feature a
physician assistant in regards to how to set up a DNR, DPOA, and resources that may include
how to get a second opinion. The video will also feature an end of life doula.
The following questions will be included in the script:
● How do patients find alternative support groups?
● How do patients set up a DPOA?
● How do you set up home healthcare and what does that look like?
● How does a DNR get set up?
● How to set up hospice or end of life considerations: wills, etc. When do you suggest
starting to make this plan?
● Tell us how to set up a DPOA, what does that mean, and how to choose the appropriate
person to make your healthcare decisions.
● Tell us when or how to set up a DNR and what that means.
● What is a second opinion, and should patients consider getting one?
● What other services do you help out with? Getting equipment, helping people to
appointments?
● When is home healthcare needed and how do you set it up?
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● When should patients consider hospice and how do they set it up?

